Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Acute promyelocytic leukemia: molecular aspects]

H de Thé1

  • 1CNRS UPR, 43, Hôpital Saint-Louis, Paris.

Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales
|January 1, 1995
PubMed
Summary

Acute promyelocytic leukemia, a cancer model, demonstrates differentiation therapy using retinoic acid. This treatment targets the specific PML/RAR fusion genetic lesion causing the disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: The tumor suppressor protein PML controls apoptosis induced by the HIV-1 envelope.

Cell death and differentiation·2026
Same author

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen.

British journal of cancer·2014
Same author

Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.

Leukemia·2012
Same author

(+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo.

Leukemia·2011
Same author

A refined molecular taxonomy of breast cancer.

Oncogene·2011
Same author

Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.

British journal of cancer·2011

Area of Science:

  • Cancer Biology
  • Hematology
  • Molecular Oncology

Context:

  • Acute promyelocytic leukemia (APL) serves as a crucial model in cancer biology.
  • It was the first cancer demonstrating successful differentiation therapy.
  • The t(15;17) translocation leading to the PML/RAR fusion protein is the molecular driver.

Purpose:

  • To elucidate the molecular mechanisms underlying leukemogenesis in APL.
  • To understand the role of the PML/RAR fusion protein in blocking cellular differentiation.
  • To highlight the significance of retinoic acid in targeting the causative genetic lesion.

Summary:

  • APL is characterized by the PML/RAR fusion protein, which disrupts nuclear receptor function and PML's tumor-suppressive activity, causing a differentiation block.
  • Retinoic acid (RA) effectively overcomes this block, inducing terminal differentiation in leukemic cells.
  • This targeted approach represents a landmark in cancer therapy, directly addressing the genetic cause.

Impact:

  • Established differentiation therapy as a viable treatment strategy for cancers.
  • Provided fundamental insights into the molecular pathogenesis of acute promyelocytic leukemia.
  • Demonstrated the potential of targeting specific genetic lesions for effective cancer treatment.

Related Experiment Videos